Justin Kim
Stock Analyst at Oppenheimer
(1.31)
# 3,674
Out of 5,150 analysts
38
Total ratings
40%
Success rate
-2.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Outperform | $44 → $50 | $26.80 | +86.57% | 5 | Dec 4, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $17 → $16 | $6.99 | +128.90% | 2 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $19.86 | +101.41% | 6 | Nov 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $62.27 | +70.23% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $33.73 | +157.93% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $39.65 | -34.43% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $5.20 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $15.04 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $8.57 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $79.45 | -25.74% | 1 | Jul 18, 2022 |
Pharvaris
Dec 4, 2025
Maintains: Outperform
Price Target: $44 → $50
Current: $26.80
Upside: +86.57%
Zura Bio
Aug 15, 2025
Maintains: Outperform
Price Target: $17 → $16
Current: $6.99
Upside: +128.90%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $19.86
Upside: +101.41%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $62.27
Upside: +70.23%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $33.73
Upside: +157.93%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $39.65
Upside: -34.43%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.20
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $15.04
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.57
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $79.45
Upside: -25.74%